Lung Cancer: Are we up to the Challenge?

Esposito, Luca; Conti, Daniele; Ailavajhala, Ramyasri; Khalil, Nansie; Giordano, Antonio
November 2010
Current Genomics;Nov2010, Vol. 11 Issue 7, p513
Academic Journal
Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor and it is basically due to a lack of early diagnostic tools. However, in the last years genetic and biochemical studies have provided more information about the protein and gene's mutations involved in lung tumors. Additionally, recent proteomic and microRNA's approaches have been introduced to help biomarker discovery. Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted therapy.


Related Articles

  • What's New in….  // JAAPA: Journal of the American Academy of Physician Assistants (;Dec2011, Vol. 24 Issue 12, p65 

    The article offers updates related to lung cancer, which is considered as the most common cancer around the world and the common cause of deaths among adults in the U.S. It mentions that the 7th edition of the TNM Classification of Malignant Tumours became the standard for the classification of...

  • Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation. Sithanandam, Gunamani; Ramakrishna, Gayatri; Diwan, Bhalchandra A; Anderson, Lucy M // Oncogene;7/30/98, Vol. 17 Issue 4, p493 

    Fetal mouse lung before gestation day 17 shows unique sensitivity to causation of rapidly growing tumors by N-ethylnitrosourea (ENU). Since mouse lung tumors present a mutated K-ras oncogene, we hypothesized that this special susceptibility might reflect an unusual vulnerability of the K-ras...

  • Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Jun Shen; Todd, Nevins W.; Zhang, Howard; Lei Yu; Xing Lingxiao; Yuping Mei; Guarnera, Maria; Jipei Liao; Chou, Amy; Lu, Changwan Larry; Zhengran Jiang; HongBin Fang; Katz, Ruth L.; Feng Jiang // Laboratory Investigation (00236837);Apr2011, Vol. 91 Issue 4, p579 

    Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. Developing minimally invasive techniques that can diagnose NSCLC, particularly at an early stage, may improve its outcome. Using microarray platforms, we previously identified 12 microRNAs (miRNAs) the aberrant...

  • Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Tang, Mingqing; Xu, William; Wang, Qizhao; Xiao, Weidong; Xu, Ruian // Current Genomics;Aug2009, Vol. 10 Issue 5, p336 

    Lung cancer, the leading cause of mortality in both men and women in the United States, is largely diagnosed at its advanced stages that there are no effective therapeutic alternatives. Although tobacco smoking is the well established cause of lung cancer, the underlying mechanism for lung...

  • The molecular approach to diagnosis in lung cancer. Moore, David A.; Le Quesne, John PC // British Journal of Hospital Medicine (17508460);May2015, Vol. 76 Issue 5, pC74 

    The article discusses lung cancer diagnosis using emerging technologies, as well as its role in providing better understanding of tumour biology. Topics discussed include technological advancements in lung cancer subclassification including antifolate chemotherapy and the range of genomic...

  • How Has Genetic Testing Changed Treatment Approaches for Patients With Lung Cancer? Tyson, Leslie B. // ONS Connect;Feb2012, Vol. 27 Issue 2, p15 

    The author discusses the significant contribution of genetic testing in changing the treatment approaches used for lung cancer patients. She notes research results suggesting that patients with nonsquamous non-small cell lung cancer (NSCLC) have better responses to pemetrexed than those with...

  • Loss of heterozygosity in the short arm of human chromosome 3 in sporadic lung cancer. BARRERA, LINA MARCELA; ÁLVAREZ, LIZETH MARELLY; ROLDÁN, MIGUEL IGNACIO; ORTEGA, HÉCTOR; TRIANA, OMAR; MARTÍNEZ, ALONSO // Colombia Medica;oct-dec2010, Vol. 41 Issue 4, p358 

    Introduction: Loss of Heterozygocity (LOH) in the short arm of human chromosome 3 (3p) is a frequent event in different types of sporadic tumors, including lung cancer (LC). Aim: To determine 3p LOH in LC samples using 17 microsatellite markers. Methodology: In a pilot study on volunteers,...

  • Advances on Driver Oncogenes of Squamous Cell Lung Cancer. Wei HONG; Yiping ZHANG // Chinese Journal of Lung Cancer;May2014, Vol. 17 Issue 5, p433 

    Background and objective Lung cancer is the leading cause of cancer-related deaths worldwide. Next to adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic subtype in non-small cell lung cancer. Several molecular alterations have been defined as "driver...

  • Detection of Gene Dosage in Circulating Free Plasma DNA as Biomarker for Lung Cancer. Alvarez, Alba Mayerly; Lara, Sandra Janneth Perdomo; Palacios, Diana M.; Carrillo, Edward Fabián; Herreros, Luis Gerardo García; Durán, Fidel Camacho; León, Paulina Ojeda; Aristizábal, Fabio A. // Journal of Cancer Therapy;Aug2012 Supplement, Vol. 3 Issue 4A, p343 

    The increase in the number of gene copies at specific loci is a genetic alteration frequently associated with over expression of the related protein in cancer cells. Genes whose dose is consistently augmented in cancer include those involved in cell cycle control, proliferation, apoptosis, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics